<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Demand is shifting to cloud/hybrid, low-code MES, driven by compliance, data integrity and Pharma 4.0. Opportunities span EBR, validation services, biologics, CDMOs and APAC.Dublin, Aug. 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6247579/pharmaceutical-manufacturing-execution-system?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=zn98zk&amp;utm_campaign=2330488+-+Pharmaceutical+Manufacturing+Execution+System+Market+Report+2026-2031+-+Worldwide+Growth+Driven+by+Increasing+Regulatory+Compliance+Requirements+and+Demand+for+Operational+Efficiency&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Pharmaceutical Manufacturing Execution System - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Pharmaceutical Manufacturing Execution System - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. The global pharmaceutical manufacturing execution system market is projected to grow from USD 2.29 billion in 2025 to USD 2.51 billion in 2026. By 2031, the market is forecast to reach USD 4.02 billion, expanding at a compound annual growth rate of 9.81% from 2026 to 2031. Growth is being supported by stricter regulatory requirements, rising investment in pharmaceutical digitalization, and increasing demand for real-time production visibility. Regulatory Compliance and Data Integrity Drive MES Investment Pharmaceutical and biopharmaceutical manufacturers are strengthening validated electronic systems to comply with 21 CFR Part 11 and other regulatory requirements governing electronic records, electronic signatures, and audit trails. Pharmaceutical manufacturing execution system platforms support compliance through controlled workflows, time-stamped activities, secure records, and traceable production data. The transition from paper-based and hybrid processes to electronic batch records is helping manufacturers reduce documentation errors, accelerate batch review, and improve release readiness. Review-by-exception capabilities allow quality teams to focus on deviations and critical events instead of manually reviewing complete batch documentation. Serialization requirements are also encouraging closer integration among MES, enterprise resource planning, quality management, and supply chain systems. Pharma 4.0 Accelerates Digital Manufacturing Transformation Pharma 4.0 initiatives are reshaping pharmaceutical production through connected operations, standardized workflows, advanced analytics, and flexible technology architectures. Modern MES platforms combine shop-floor execution, quality processes, serialization, and analytics to provide operators, supervisors, and quality assurance teams with timely production information. Cloud-ready, containerized, and low-code platforms are gaining attention because they can simplify system configuration, validation, and change control. Standardized master recipes and electronic work instructions also help reduce process variability and production hold times. These capabilities support deployments ranging from individual production lines to global, multi-site manufacturing networks. Implementation Cost and Complexity Remain Key Challenges High implementation costs, integration requirements, and limited internal resources can delay MES adoption, particularly among mid-sized pharmaceutical and biotechnology companies. Deploying an MES often requires coordinated changes across manufacturing, quality assurance, information technology, automation, and workforce training. Cloud-native platforms, managed services, pre-validated content, and industry-specific templates are helping reduce deployment burdens. Manufacturers are also adopting phased implementation strategies and pilot programs to align projects with site readiness and change-control capacity. However, integrating MES platforms with legacy equipment and older enterprise systems remains a significant challenge in brownfield facilities. Software Leads as Services Record Strong Growth Software accounted for 56.64% of the pharmaceutical manufacturing execution system market in 2025. Demand remains strong for electronic batch records, recipe and workflow management, deviation handling, serialization integration, audit trails, and secure system development. Services are projected to expand at a CAGR of 10.23% between 2026 and 2031. This growth reflects increasing demand for implementation, validation, system integration, training, managed support, regression testing, and lifecycle management. As manufacturers extend MES deployments across multiple facilities, service providers are playing a larger role in maintaining validated systems and supporting compliant upgrades. Cloud and SaaS Deployments Gain Momentum On-premise solutions represented 55.81% of the market in 2025, reflecting the pharmaceutical industry's established preference for direct infrastructure control. Cloud and software-as-a-service deployments, however, are expected to grow at a CAGR of 13.65% from 2026 to 2031. Cloud-based pharmaceutical MES solutions can reduce infrastructure ownership, support faster multi-site rollouts, and standardize software updates. Hybrid deployments are also becoming an important option for manufacturers that need to keep critical production execution close to the plant floor while using cloud environments for analytics, reporting, and centralized governance. Secure development practices, cybersecurity controls, validation documentation, and data sovereignty remain central to purchasing decisions. Regional Pharmaceutical MES Market Outlook North America held 37.23% of the global market in 2025, supported by mature regulatory frameworks, established pharmaceutical manufacturers, biotechnology clusters, and major contract development and manufacturing organizations. Regional investment is focused on cloud-enabled MES, electronic batch records, serialization, review-by-exception, and standardized multi-site operating models. Asia-Pacific is forecast to be the fastest-growing regional market, registering a CAGR of 15.83% between 2026 and 2031. Expansion in biologics manufacturing, new pharmaceutical facilities, and continued growth among contract development and manufacturing organizations are increasing demand for validated digital production systems. Manufacturers across the region are prioritizing interoperability, modular MES content, cloud scalability, and integration with legacy equipment. Europe continues to generate steady demand as pharmaceutical companies strengthen data governance, cybersecurity, serialization, and quality-focused digital manufacturing. Cloud and hybrid MES deployments are enabling manufacturers to retain local operational control while centralizing analytics, master data, and governance across multiple facilities. Together, these trends position the pharmaceutical manufacturing execution system market for sustained global expansion through 2031. Key Topics Covered: 1 Introduction 1.1 Study Assumptions &amp; Market Definition 1.2 Scope of the Study 2 Research Methodology 3 Executive Summary 4 Market Landscape 4.1 Market Overview 4.2 Market Drivers 4.2.1 Regulatory Compliance and Data Integrity Requirements 4.2.2 Pharma 4.0 Digitalization Momentum (ISPE) 4.2.3 Need For Real-Time Visibility and End-To-End Traceability 4.2.4 Growth In Biologics, Cell and Gene Therapies 4.2.5 Computer Software Assurance (CSA) Enabling Risk-Based Validation 4.2.6 Continuous Manufacturing (ICH Q13) and Real-Time Release 4.3 Market Restraints 4.3.1 High Implementation Cost and Program Complexity 4.3.2 Integration With Legacy Systems and Data Silos 4.3.3 Validation Talent Gaps and CSV/CSA Transition Bottlenecks 4.3.4 Master Data and Process Standardization Readiness Shortfalls 4.4 Value / Supply-Chain Analysis 4.5 Regulatory Landscape 4.6 Technological Outlook 4.7 Porters Five Forces Analysis 4.7.1 Threat of New Entrants 4.7.2 Bargaining Power of Buyers 4.7.3 Bargaining Power of Suppliers 4.7.4 Threat of Substitutes 4.7.5 Competitive Rivalry 5 Market Size &amp; Growth Forecasts (Value, USD) 5.1 By Component 5.1.1 Software 5.1.2 Services 5.2 By Deployment 5.2.1 On-Premise 5.2.2 Cloud / SaaS 5.3 By Functionality 5.3.1 Electronic Batch Records (EBR) 5.3.2 Recipe / Workflow Management 5.3.3 Equipment Management 5.3.4 Deviation &amp; CAPA Integration 5.3.5 Serialization Integration 5.3.6 Others 5.4 By End User 5.4.1 Pharmaceutical Manufacturers 5.4.2 Biopharmaceutical Manufacturers 5.4.3 Cell &amp; Gene Therapy Manufacturers 5.4.4 CMOs / CDMOs 5.5 By Geography 5.5.1 North America 5.5.1.1 United States 5.5.1.2 Canada 5.5.1.3 Mexico 5.5.2 Europe 5.5.2.1 Germany 5.5.2.2 United Kingdom 5.5.2.3 France 5.5.2.4 Italy 5.5.2.5 Spain 5.5.2.6 Rest of Europe 5.5.3 Asia-Pacific 5.5.3.1 China 5.5.3.2 India 5.5.3.3 Japan 5.5.3.4 Australia 5.5.3.5 South Korea 5.5.3.6 Rest of Asia-Pacific 5.5.4 Middle East and Africa 5.5.4.1 GCC 5.5.4.2 South Africa 5.5.4.3 Rest of Middle East and Africa 5.5.5 South America 5.5.5.1 Brazil 5.5.5.2 Argentina 5.5.5.3 Rest of South America 6 Competitive Landscape 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products &amp; Services, and Recent Developments) 6.3.1 ABB Ltd. 6.3.2 Apprentice.io, Inc. 6.3.3 COPA-DATA GmbH 6.3.4 Critical Manufacturing, S.A. 6.3.5 Dassault Systemes SE 6.3.6 Emerson Electric Co. 6.3.7 Honeywell International Inc. 6.3.8 Korber AG 6.3.9 MasterControl, Inc. 6.3.10 MPDV Mikrolab GmbH 6.3.11 Parsec Automation Corporation 6.3.12 POMS Corporation 6.3.13 Rockwell Automation, Inc. 6.3.14 SAP SE 6.3.15 Schneider Electric SE 6.3.16 Siemens AG 6.3.17 Yokogawa Electric Corporation 7 Market Opportunities &amp; Future Outlook 7.1 White-space &amp; Unmet-need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6247579/pharmaceutical-manufacturing-execution-system?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=zn98zk&amp;utm_campaign=2330488+-+Pharmaceutical+Manufacturing+Execution+System+Market+Report+2026-2031+-+Worldwide+Growth+Driven+by+Increasing+Regulatory+Compliance+Requirements+and+Demand+for+Operational+Efficiency&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/o70ot1</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZWY0NjlkYzYtZTZjYi00NTI1LWFiNGYtMTVhNjBmODBhZWQwLTEwMjY3MzctMjAyNi0wOC0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Pharmaceutical Manufacturing Execution System Market Report 2026-2031 - Worldwide Growth Driven by Increasing Regulatory Compliance Requirements and Demand for Operational Efficiency

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn